Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Dana-Farber Cancer Institute at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Dana-Farber Cancer Institute brings 90 presentations to ASH 2026 in New Orleans. Its program centres on lymphoma, Waldenström macroglobulinemia and myeloma, including trials of bispecific antibodies and BTK inhibitors. It also looks at care access, with titles on workforce, healthcare reform and CAR-T manufacturing in lower-income countries.

OrganizationASH 2026 Attendance
Hospitals & cancer centres
Harvard-affiliated cancer treatment and research center in Boston, Massachusetts.
Symposium
Fri Dec 11
7:00am–10:00am
MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum
Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia.
Leukemias
Symposium
Fri Dec 11
11:00am–2:00pm
Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum
Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects.
Symposium hosted by PRIME Education
Lymphoma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Cases and Conversations: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies
Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome.
Leukemias
Symposium
Fri Dec 11
11:00am–2:00pm
Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making
Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia.
Leukemias
Symposium
Fri Dec 11
11:00am–2:00pm
Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies
Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care
Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing.
Myeloma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment
Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk.
Symposium hosted by PeerView Institute for Medical Education
Lymphoma · New drugs
Session
Fri Dec 11
4:00pm–4:50pm
Identifying Biological Vulnerabilities in TP53 mutations
Weak points of p53-mutated cells, from allele states and co-mutations to the microenvironment, plus difficulties in detecting and interpreting variants.
Leukemias
Session
Fri Dec 11
5:04pm–5:53pm
Symposium
Fri Dec 11
7:00pm–10:00pm
Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia
Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs.
Leukemias
Session
Sat Dec 12
9:30am–10:45am
Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward
Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma.
Myeloma · Blood biology
Talk
Sat Dec 12
9:30am–10:45am
Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function
Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target.
Myeloma · Blood biology
Session
Sat Dec 12
2:00pm–3:15pm
Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS
Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity.
Leukemias · AI & data
Talk
Sat Dec 12
2:00pm–3:15pm
Dealing with Workforce Challenges in Classical Hematology
What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap.
Patient care · AI & data
Talk
Mon Dec 14
2:45pm–4:00pm
From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs
Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries.
Cell & gene · Patient care
Talk
Mon Dec 14
4:30pm–5:45pm
Targeting Acute and Chronic GVHD with Effective New Therapies
Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells.
Cell & gene

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Dana-Farber Cancer Institute

Tell us what you sell and we’ll find the people at Dana-Farber Cancer Institute most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction